Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL)

Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Xiaoyang Su, PhD, Ying Chen, PhD, Maisarah Mokhtar, B.S, Gregory Dolnikowski, Frederick Lansigan, MD, William B Kinlaw, III, MD, Sandeep Dave, MD, Andrew M. Evens, DO, MSc

Blood (2019) 134 (Supplement_1): 1573.

https://doi.org/10.1182/blood-2019-126382

Published: 2019

Journal Articles

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Giovanni Caocci, MD, Martino Deidda, Antonio Noto, Christian Cadeddu, Marianna Greco, Maria Pina Simula, Olga Mulas, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercuro, Giorgio La Nasa

Blood (2019) 134 (Supplement_1): 4144.

https://doi.org/10.1182/blood-2019-124323

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

Anthony Quagliano, BS, Anilkumar Gopalakrishnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 2628.

https://doi.org/10.1182/blood-2019-129198

Published: 2019

Journal Articles

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

Aksinija A Kogan, BS, MS, Michael Topper, BS, Susannah C Shissler, BS, Michael S Lee, BS, Dominique R Bollino, BS, Eun Yong Choi, Rena G Lapidus, PhD, Li Li, MD PhD, Donald Small, MD PhD, Maria R. Baer, MD, Tonya J Webb, PhD, Stephen Baylin, MD, Feyruz V. Rassool, BSc, PhD

Blood (2018) 132 (Supplement 1): 3886.

https://doi.org/10.1182/blood-2018-99-117294

Published: 2018

Journal Articles

Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 3938.

https://doi.org/10.1182/blood-2018-99-119880

Published: 2018

Journal Articles

Activated Pentose Phosphate Pathway Mediated By Fbp-1 Upregulation Supports Progression of Acute Myeloid Leukemia with High EVI-1 Expression

Hideaki Mizuno, MD, Yuki Kagoya, MD PhD, Junji Koya, MD PhD, Yosuke Masamoto, MD PhD, Mineo Kurokawa, MD PhD

Blood (2018) 132 (Supplement 1): 757.

https://doi.org/10.1182/blood-2018-99-118922

Published: 2018

Journal Articles

Adenosine A2B Receptor Controls Erythroid Lineage Commitment in Stress Erythropoiesis By Promoting Metabolic Reprogramming

Hong Liu, MD, Rongrong Liu, Travis Nemkov, Jacob Couturier, PhD, Long Liang, Anren Song, PhD, Shushan Zhao, MD PhD, Kaiqi Sun, PhD, Morayo Adebiyi, PhD, Yuan Edward Wen, Alexander Wen, Jing Liu, PhD, Rodney Kellems, PhD, Angelo D'Alessandro, PhD, Michael Blackburn, PhD, Yang Xia, MD PhD

Blood (2018) 132 (Supplement 1): 845.

https://doi.org/10.1182/blood-2018-99-114075

Published: 2018

Journal Articles

Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas

Ipsita Pal, PhD, Yu Ri Kim, MD, Luigi Scotto, PhD, Mark R Lipstein, PhD, Abdullah Mahmood Ali, PhD, Siddhartha Mukherjee, MD PhD, Susan E. Bates, MDPhD, Owen A. O'Connor, MD, PhD, Changchun Deng, MD PhD

Blood (2017) 130 (Supplement 1): 2809.

https://doi.org/10.1182/blood.V130.Suppl_1.2809.2809

Published: 2017

Journal Articles

Global and Targeted Metabolic Profiling Identifies Metabolic Markers for FLT3-ITD in Pediatric AML Patients

Bradley Stockard, PharmD, Joy Guingab, PhD, Timothy Garrett, PhD, Stanley Pounds, PhD, Jeffrey E Rubnitz, MD PhD, Jatinder Lamba, PhD

Blood (2017) 130 (Supplement 1): 5105.

https://doi.org/10.1182/blood.V130.Suppl_1.5105.5105

Published: 2017

Journal Articles

HEME Degradation Enzyme Biliverdin IXb Reductase Is Required for Stem Cell Glutamine Metabolism

Zongdong Li, PhD, Wadie F. Bahou, MD

Blood (2017) 130 (Supplement 1): 3763.

https://doi.org/10.1182/blood.V130.Suppl_1.3763.3763

Published: 2017

Journal Articles

First Report of Severe Folate Deficiency in Women Treated with Olaparib for Relapsed Ovarian Cancer

Jamile M. Shammo, MD, Lydia Usha, MD, Kristin Richardson, MD, Elizabeth Jane Elliott, BS, DO, Parameswaran Venugopal, MD, Timothy M. Kuzel, MD, Melody Cobleigh, MD, Summer Dewdney, MD

Blood (2017) 130 (Supplement 1): 4748.

https://doi.org/10.1182/blood.V130.Suppl_1.4748.4748

Published: 2017

Journal Articles

Thymidine Phosphorylase Exerts Complex Effects on Bone Resorption and Formation in Myeloma

Huan Liu, PhD, Zhiqiang Liu, PhD, Juan Du, MD, Jin He, M.S., Pei Lin, MD, Amini Behrang, MD, Michael W Starbuck, M.S., Nora M Novane, MD, Jatin J. Shah, MD, Richard Eric Davis, MD, Jian Hou, MD, Robert Gagel, MD, Jing Yang, PhD

Blood (2016) 128 (22): 1135.

https://doi.org/10.1182/blood.V128.22.1135.1135

Published: 2016

Journal Articles

Biallelic Mutations in PARP4 Are Linked to a Variant Form of Congenital Dyserythropoietic Anemia

Paola Bianchi, PhD, Elisa Fermo, PhD, Jennifer C Eng, Jacob C Ulirsch, Cristina Vercellati, BSc, Paola Braidotti, MD, Gordon Hildick-Smith, Timothy J Satchwell, PhD, Stephanie Pellegrin, PhD, Alberto Zanella, MD, Wilma Barcellini, MD, Barry H. Paw, MD, PhD, Ashley Mark Toye, PhD, Vijay G Sankaran, MD PhD

Blood (2015) 126 (23): 272.

https://doi.org/10.1182/blood.V126.23.272.272

Published: 2015

Journal Articles

Cell Line-Dependent Synergy Between the PARP Inhibitor Veliparib and the Proteasome Inhibitor Bortezomib in the Killing of Myeloma Cells

Alex Xu, B.A., Amitabha Mazumder, MD, James A. Borowiec, PhD

Blood (2015) 126 (23): 5556.

https://doi.org/10.1182/blood.V126.23.5556.5556

Published: 2015

Journal Articles

Demethylating Agents Reprogram Myelodysplastic Syndrome and Leukemia Cells, Sensitizing Them To Poly-(ADP)-Ribose Polymerase Inhibitors

Carine Robert, PhD, Nidal E Muvarak, MS, Vu H. Duong, MD, Maria R. Baer, MD, Stephen B. Baylin, MD, Feyruz Rassool, PhD

Blood (2013) 122 (21): 3778.

https://doi.org/10.1182/blood.V122.21.3778.3778

Published: 2013

Journal Articles

Thymidylate Synthase Inhibition with the Novel Fluoropyrimidine FdUMP[10] Is Highly Effective Against Acute Lymphoblastic Leukemia

Timothy Pardee, MD, PhD, Jamie Jennings-Gee, PhD, Peter Alexander, BA, William Gmeiner, PhD

Blood (2012) 120 (21): 1505.

https://doi.org/10.1182/blood.V120.21.1505.1505

Published: 2012

Journal Articles

B-Lymphocyte Development Is Impaired by FLT3/ITD Signaling in Knock-in Mice Because of Defective Non-Homologous End-Joining.

Li Li, MD, PhD, Li Zhang, PhD, Jinshui Fan, PhD, Kathleen E Greenberg, BS, Stephen Desiderio, MD, PhD, Feyruz V. Rassool, PhD, Donald Small, MD, PhD

Blood (2009) 114 (22): 184.

https://doi.org/10.1182/blood.V114.22.184.184

Published: 2009

Journal Articles

OSU-DY7, a Novel D -Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway.

Li-Yuan Bai, MD, Yihui Ma, Samuel K Kulp, Shu-Huei Wang, PhD, Chang-Fang Chiu, MD, DMS, Frank Frissora, Xiaokui Mo, David Jarjoura, John C. Byrd, Ching-Shih Chen, Natarajan Muthusamy, DVM., PhD

Blood (2009) 114 (22): 3778.

https://doi.org/10.1182/blood.V114.22.3778.3778

Published: 2009

NARROW

Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL)

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML)

Activated Pentose Phosphate Pathway Mediated By Fbp-1 Upregulation Supports Progression of Acute Myeloid Leukemia with High EVI-1 Expression

Adenosine A2B Receptor Controls Erythroid Lineage Commitment in Stress Erythropoiesis By Promoting Metabolic Reprogramming

Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas

Global and Targeted Metabolic Profiling Identifies Metabolic Markers for FLT3-ITD in Pediatric AML Patients

HEME Degradation Enzyme Biliverdin IXb Reductase Is Required for Stem Cell Glutamine Metabolism

First Report of Severe Folate Deficiency in Women Treated with Olaparib for Relapsed Ovarian Cancer

Thymidine Phosphorylase Exerts Complex Effects on Bone Resorption and Formation in Myeloma

Biallelic Mutations in PARP4 Are Linked to a Variant Form of Congenital Dyserythropoietic Anemia

Cell Line-Dependent Synergy Between the PARP Inhibitor Veliparib and the Proteasome Inhibitor Bortezomib in the Killing of Myeloma Cells

Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia

Demethylating Agents Reprogram Myelodysplastic Syndrome and Leukemia Cells, Sensitizing Them To Poly-(ADP)-Ribose Polymerase Inhibitors

Thymidylate Synthase Inhibition with the Novel Fluoropyrimidine FdUMP[10] Is Highly Effective Against Acute Lymphoblastic Leukemia

B-Lymphocyte Development Is Impaired by FLT3/ITD Signaling in Knock-in Mice Because of Defective Non-Homologous End-Joining.

OSU-DY7, a Novel D -Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only